ArticleJournal of enzyme inhibition and medicinal chemistry2018
The hop-derived compounds xanthohumol, isoxanthohumol and 8-prenylnaringenin are tight-binding inhibitors of human aldo-keto reductases 1B1 and 1B10.
Article in Journal of enzyme inhibition and medicinal chemistry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 36 citations in OpenAlex.
- ExploringMolecules (Basel, Switzerland) · 2026Article
- Biotransformation of Xanthohumol by Entomopathogenic Filamentous Fungi.International journal of molecular sciences · 2024Article
- Aldo-keto reductases: Role in cancer development and theranostics.Oncology research · 2024Review
- Anti-Influenza Virus Activity ofFoods (Basel, Switzerland) · 2023Review
- Phytochemistry and pharmacology of natural prenylated flavonoids.Archives of pharmacal research · 2023Review
- Effect of Structural Differences in Naringenin, Prenylated Naringenin, and Their Derivatives on the Anti-Influenza Virus Activity and Cellular Uptake of Their Flavanones.Pharmaceuticals (Basel, Switzerland) · 2022Article
- The Potent Phytoestrogen 8-Prenylnaringenin: A Friend or a Foe?International journal of molecular sciences · 2022Review
- Antioxidants in Hops: Bioavailability, Health Effects and Perspectives for New Products.Antioxidants (Basel, Switzerland) · 2022Review
- Review
- The Role of AKR1B10 in Physiology and Pathophysiology.Metabolites · 2021Review
- A New Chalcone Derivative C49 Reverses Doxorubicin Resistance in MCF-7/DOX Cells by Inhibiting P-Glycoprotein Expression.Frontiers in pharmacology · 2021Article
- Prevention of Fine Dust-Induced Vascular Senescence byAntioxidants (Basel, Switzerland) · 2020Article
- Wine or Beer? Comparison, Changes and Improvement of Polyphenolic Compounds during Technological Phases.Molecules (Basel, Switzerland) · 2020Review
- The Modulation of Phase II Drug-Metabolizing Enzymes in Proliferating and Differentiated CaCo-2 Cells by Hop-Derived Prenylflavonoids.Nutrients · 2020Article
- Evaluation of the Anti-Diabetic Activity of Some Common Herbs and Spices: Providing New Insights with Inverse Virtual Screening.Molecules (Basel, Switzerland) · 2019Review
- Selective Inhibition of Human AKR1B10 byMolecules (Basel, Switzerland) · 2018Article
- Whole-transcriptome Analysis of Fully Viable Energy Efficient Glycolytic-null Cancer Cells Established by Double Genetic Knockout of Lactate Dehydrogenase A/B or Glucose-6-Phosphate Isomerase.Cancer genomics & proteomicsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Xanthohumol (XN), a prenylated chalcone unique to hops (Humulus lupulus) and two derived prenylflavanones, isoxanthohumol (IX) and 8-prenylnaringenin (8-PN) gained increasing attention as potential anti-diabetic and cancer preventive compounds. Two enzymes of the aldo-keto reductase (AKR) superfamily are notable pharmacological targets in cancer therapy (AKR1B10) and in the treatment of diabetic complications (AKR1B1). Our results show that XN, IX and 8-PN are potent uncompetitive, tight-binding inhibitors of human aldose reductase AKR1B1 (K
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.